Search Results - Xing Sun
- Showing 1 - 5 results of 5
-
1
Status and path of intergenerational transmission of poverty in rural China: A human capital investment perspective by Yun-li BAI, Lin-xiu ZHANG, Ming-xing SUN, Xiang-bo XU
Published 2021-04-01This paper focused on the intergenerational transmission of poverty in rural China by estimating the intergenerational transmission of earnings and stated its mechanism from the perspective of human capital investment before children participated in the labor market. The data used in this study were...
Get full text
Article -
2
Giant Aortic Aneurysm in Refractory Behçet’s Disease Shrank with Tocilizumab Treatment: A Case Report by Zi‐Yi Song, Xin Zhi, Jia‐Yi Geng, Xing Sun, Tian Liu, Zhan‐Guo Li
Published 2025-07-01Behçet disease (BD) is characterized by recurrent oral and genital ulcers, skin lesions, and vascular involvement. Giant aortic aneurysm, a life‐threatening complication of BD, often proves refractory to conventional therapies. Here, we present the case of a 71‐year‐old man with a 40‐year history of...
Get full text
Article -
3
Ultrasound-Assisted Enhancement of Gel Properties in <i>Hypomesus olidus</i> Surimi by Yuan Fu, Guochuan Jiang, Xing Sun, Shuibing Yang, Jiahang Yu, Xuejun Liu, Liyan Wang, Shuangjie Zhu
Published 2025-07-01Surimi gel quality is crucial for seafood product texture and water retention, yet conventional processing often fails to maximize the potential of underutilized species like <i>Hypomesus olidus</i>. This study investigated the effects of ultrasonic power (100, 200, 400, 800 W) and time...
Get full text
Article -
4
SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles by Ting Zhang, Jianyan Xu, Junzhao Yin, Yun Gao, Hanwen Zheng, Beibei Fu, Jiakang Sun, Zhibin Xu, Shiwei Tu, Yuchang Mao, Weiyun Wen, Bolei Qu, Lingfeng You, Zhendong Xue, Xing Sun, Dan Cao, Jun Feng, Min Hu, Feng He
Published 2025-01-01Get full text
Article -
5
SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. by Ting Zhang, Jianyan Xu, Junzhao Yin, Yun Gao, Hanwen Zheng, Beibei Fu, Jiakang Sun, Zhibin Xu, Shiwei Tu, Yuchang Mao, Weiyun Wen, Bolei Qu, Lingfeng You, Zhendong Xue, Xing Sun, Dan Cao, Jun Feng, Min Hu, Feng He
Published 2025-01-01HER2-targeting antibody-drug conjugates (ADCs), especially trastuzumab deruxtecan (T-DXd), have revolutionized the treatment landscape of HER2-expressing or mutant cancers. However, undesired adverse events are still inevitable and it is necessary to discover a HER2-directed ADC with better safety p...
Get full text
Article